Search
Lofexidine
go.drugbank.com/drugs/DB04948ApprovedInvestigationalLofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. … [A33084] It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine.
Categories: Drugs Used in Opioid Dependence, Drugs Used in Addictive DisordersImlunestrant
go.drugbank.com/drugs/DB19043ApprovedInvestigationalThe FDA approved imlunestrant on September 25, 2025 [L54051] as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with … Imlunestrant is a brain-penetrant selective estrogen receptor antagonist and degrader.
Pitolisant
go.drugbank.com/drugs/DB11642ApprovedInvestigationalPitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. … [A32023] Adolescent patients with cataplexy also experienced a slight improvement in the frequency and severity of symptoms [A32023]; however, the safety of use in adolescent or paediatric patients have
Nerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigational[L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade. … [L54126] Compared to pan-PDE4 inhibitors, selective PDE4B inhibitors are associated with a lower potential for gastrointestinal adverse events.[A274581] On December 19, 2025, the U.S.
Grepafloxacin
go.drugbank.com/drugs/DB00365ApprovedWithdrawnDue to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States … Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseIsoniazid
go.drugbank.com/drugs/DB00951ApprovedInvestigationalAntibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Mixtures: PRO TB 4, PRO TB 2Categories: Antiinfectives for Systemic Use, Drugs for Treatment of TuberculosisAmbrisentan
go.drugbank.com/drugs/DB06403ApprovedInvestigationalAmbrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. … It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening.
Categories: Antihypertensives for Pulmonary Arterial HypertensionProducts: AMBRISEN 1A PHARMA 5MG, AMBRISENTAN AL 5MG FTAAlteplase
go.drugbank.com/drugs/DB00009ApprovedInvestigationalAlteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent.[L43125] It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. … [A252330,L43125] Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells.
Mixtures: Activase RT-PA, Lysatec RT - PaSynonyms: t-PA, rt-PARubidium Rb-82
go.drugbank.com/drugs/DB09479ApprovedInvestigationalIt is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected … Rubidium chloride Rb-82 injection is a sterile nonpyrogenic solutions of rubidium Rb 82 chloride.
Influenza A virus A/Hong Kong/2671/2019 IVR-208 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15704ApprovedInvestigationalInactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Vaxigrip Tetra, Suspension for Injection in Pre-filled Syringe, FLUAD Injektionssuspension in einer FertigspritzeCategories: Inactivated Influenza A Virus Vaccine